2023 Was a tough calendar year for the biopharma field, with various firms downsizing and restructuring their workforces to stay afloat. There are indications of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifestyle sciences field during the latter Element of 2023 and possess ongoing their upswing https://sites.google.com/view/bio-sites/blog